New site coming soon

FROM SCIENCE TO BUSINESS

 

 

 

 

Key Elements
 A full day dedicated to innovation in health and biomedical research.
A unique platform connecting academia, startups, companies, and public institutions.
Great visibility for sponsors and partners.
A well-structured agenda with plenary sessions, keynotes, and B2B meetings 


What CID offers
A unique matchmaking environment between public and private players.
Visibility and recognition for over 30 top-tier French research cohorts.
A national dynamic supporting translational research.
An effective communication tool for funders, industry and labs

 

2025 Priority Themes
Prevention and Public Health
Artificial Intelligence and Health Data
Translational Research and Innovative Clinical Trials
Personalized Medicine and Patient Pathways
 

 

More than 30 French excellence cohorts
CID showcases over 30 nationally recognized French cohorts in fields such as cardiometabolic, neurology, infectious diseases, oncology, and more.
Each cohort will present its results, challenges, and opportunities for collaborations

 

 

Provisional Program – Cohort Innovation Day 2025

Morning:

Plenary Sessions & Round Tables
08:30 – 09:00: Opening remarks
Speakers: Marc, Christian (INSERM)
09:00 – 10:00: First Round Table – Public-Private Partnerships (PPP)
Moderator to be confirmed
10:00 – 10:45: Presentation of scientific projects from 3 cohorts
Moderator to be confirmed


10:45 – 11:00: Coffee break


11:00 – 12:00: Second Round Table – Topic to be confirmed
Moderator to be confirmed
12:00 – 12:30: Presentation of scientific projects from 2 cohorts
Moderator to be confirmed
12:30 – 12:45: Sponsor keynote or intervention
Speaker to be confirmed
12:45 – 13:15: European Keynote

 

Lunch:
13:30 – 14:00: Lunch break
Afternoon: B2B Meetings
15 tables – 8 slots – up to 120 meetings possible


Be the first to join — pre-register now for the 2025 edition of Cohort Innovation Day!

Stay up-to-date with the latest news on CID, register here

 

 

Sponsorship – Why Support CID 2025?
Becoming a sponsor of Cohort Innovation Day 2025 means positioning your organization at the heart of cutting-edge biomedical research and innovation.
Support the event, gain visibility among key players in health research, and help foster collaborations between public cohorts and private stakeholders.

Download the sponsorship brochure to explore all our partnership opportunities and pricing details.

 ​

 

rir 2013 lg

The 5th International R&D Dating will take place on October 24th in the “Carrousel du Louvre” right in the heart of Paris, on the theme of «Inflammation and inflammatory diseases». This topic, chosen by ARIIS and AVIESAN, is in agreement with the recommendation of the 5th meeting of the Strategic Council of Industries of Health (CSIS) held in January 2012.

Inflammation is part of a complex physiological process and plays a crucial role in the tissue response to harmful stimuli. However, acute or chronic inflammation can induce many diseases. Progress in the elucidation of the mechanisms that regulate inflammation and a reinforced organization of the patient treatment may allow a better medical care and the development of new anti-inflammatory drugs.

Inflammation is a worldwide priority for public health. In France, more than 80 research teams are working on inflammation and/or inflammatory diseases. These teams have made major progresses in the molecular and cellular bases of inflammation, as well as on clinical research, epidemiology, public health and translational research. Altogether, the results obtained result in a better understanding of inflammatory diseases.

The research developed in France is specifically focused on several aspects of inflammation and inflammatory diseases: elucidation of the cellular and molecular mechanisms that regulate inflammation; research on the interactions between components of the immune system during the inflammatory response and its chronicity; development of new experimental models of inflammatory pathologies and technological improvement to follow the onset and the evolution of the inflammatory response; role of the tissue environment and development of new cellular or molecular products targeting the pathways implicated in the early and late stages of the inflammatory response and inflammatory diseases without efficient therapies. Finally, genomic studies leads to the identification of molecular signatures that can be transferred to clinical studies and will allow better diagnosis, prognosis and improvement of treatments of inflammatory diseases.